• 中国精品科技期刊
  • 《中文核心期刊要目总览》收录期刊
  • RCCSE 中国核心期刊(5/114,A+)
  • Scopus收录期刊
  • 美国《化学文摘》(CA)收录期刊
  • WHO 西太平洋地区医学索引(WPRIM)收录期刊
  • 《中国科学引文数据库(CSCD)》核心库期刊 (C)
  • 中国科技核心期刊
  • 中国科技论文统计源期刊
  • 《日本科学技术振兴机构数据库(中国)》(JSTChina)收录期刊
  • 美国《乌利希期刊指南》(UIrichsweb)收录期刊
  • 中华预防医学会系列杂志优秀期刊(2019年)

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

新型冠状病毒Omicron变异株的流行病学特征及其科学防控建议

吴俣 刘珏 刘民 梁万年

吴俣, 刘珏, 刘民, 梁万年. 新型冠状病毒Omicron变异株的流行病学特征及其科学防控建议[J]. 中华疾病控制杂志, 2022, 26(5): 497-501. doi: 10.16462/j.cnki.zhjbkz.2022.05.001
引用本文: 吴俣, 刘珏, 刘民, 梁万年. 新型冠状病毒Omicron变异株的流行病学特征及其科学防控建议[J]. 中华疾病控制杂志, 2022, 26(5): 497-501. doi: 10.16462/j.cnki.zhjbkz.2022.05.001
WU Yu, LIU Jue, LIU Min, LIANG Wan-nian. Epidemiologic features and scientific prevention and control advice of SARS-CoV-2 Omicron variant[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2022, 26(5): 497-501. doi: 10.16462/j.cnki.zhjbkz.2022.05.001
Citation: WU Yu, LIU Jue, LIU Min, LIANG Wan-nian. Epidemiologic features and scientific prevention and control advice of SARS-CoV-2 Omicron variant[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2022, 26(5): 497-501. doi: 10.16462/j.cnki.zhjbkz.2022.05.001

新型冠状病毒Omicron变异株的流行病学特征及其科学防控建议

doi: 10.16462/j.cnki.zhjbkz.2022.05.001
当前,全球进入了新冠疫情第四轮流行高峰期,本轮新增病例多以Omicron变异株感染为主,新增病例和无症状感染者呈现聚集性、点多、面广、频发的特点,疫情形势复杂严峻。本刊坚持“人民至上、生命至上”的抗疫理念,邀请北京大学公共卫生学院刘民教授以及清华大学万科公共卫生与健康学院梁万年教授对新型冠状病毒Omicron变异株的流行病学特征进行了详细的介绍,并对其科学防控提出了宝贵的建议。希望本文的及时出版能够为广大医务工作者提供Omicron变异株防控的相关知识,为抗击本轮疫情的胜利做出贡献。
基金项目: 

科技创新2030重大项目 2021ZD0114104

科技创新2030重大项目 2021ZD0114105

科技创新2030重大项目 2021ZD0114101

国家自然科学基金 71934002

国家自然科学基金 72122001

详细信息
    通讯作者:

    梁万年,E-mail: liangwn@tsinghua.edu.cn

    刘民,E-mail: liumin@bjmu.edu.cn

  • 中图分类号: R181;R373.1

Epidemiologic features and scientific prevention and control advice of SARS-CoV-2 Omicron variant

Funds: 

National Key R & D Program of China 2021ZD0114104

National Key R & D Program of China 2021ZD0114105

National Key R & D Program of China 2021ZD0114101

National Natural Science Foundation of China 71934002

National Natural Science Foundation of China 72122001

More Information
  • 摘要: 目前全球COVID-19疫情仍处于大流行状态。南非于2021年11月24日首次向WHO报告了Omicron变异株感染病例,此后该变异株迅速传播至全球多个国家和地区,已成为当前全球流行的主要优势株。Omicron变异株与SARS-CoV-2野生株或其他变异株相比,具有所致疾病潜伏期短、代际间隔小、病毒传播快、无症状感染者比例高以及病死率低等特点。实践证明,中国坚持“人民至上、生命至上”的抗疫理念、“外防输入、内防反弹”的总策略、“动态清零”的总方针,目前所采取的综合防控措施能够有效应对Omicron变异株。建议现阶段坚持“动态清零”总方针,加强疫情境外输入风险管理、加快推进老年人群疫苗接种、加快特异性药物研发与上市以及提前做好医疗卫生资源储备等措施,为未来的防控决策与疫情应对做好充分准备。
  • [1] WHO. Tracking SARS-CoV-2 variants [EB/OL]. (2022-04-06) [2022-04-07]. https://www.who.int/en/activities/tracking-SARS-CoV-2-variants.
    [2] WHO. Classification of Omicron (B. 1.1.529): SARS-CoV-2 Variant of Concern [EB/OL]. (2021-11-26) [2022-04-07]. https://www.who.int/news/item/26-11-2021-classification-of-Omicron-(b.1.1.529)-sars-cov-2-variant-of-concern.
    [3] WHO. Tracking of variants [EB/OL]. (2022-04-06) [2022-04-07]. https://www.gisaid.org/hcov19-variants.
    [4] WHO. Weekly epidemiological update on COVID-19-5 April 2022[EB/OL]. (2022-04-05) [2022-04-07]. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---5-april-2022.
    [5] Guardian M. New COVID-19 variant is a concern as cases show a sharp increase in Gauteng [EB/OL]. (2021-11-25) [2022-04-07]. https://mg.co.za/coronavirus-essential/2021-11-25-new-covid-19-variant-is-a-concern-as-cases-show-a-sharp-increase-in-gauteng.
    [6] Torjesen I. COVID-19: Omicron may be more transmissible than other variants and partly resistant to existing vaccines, scientists fear [J]. BMJ, 2021, 375: n2943. DOI: 10.1136/bmj.n2943.
    [7] European Centre for Disease Prevention and Control. SARS-CoV-2 variants dashboard [EB/OL]. (2022-04-06) [2022-04-07]. https://www.ecdc.europa.eu/en/covid-19/situation-updates/variants-dashboard.
    [8] Tian D, Sun Y, Xu H, et al. The emergence and epidemic characteristics of the highly mutated SARS-CoV-2 Omicron variant [J]. J Med Virol, 2022. DOI: 10.1002/jmv.27643.
    [9] Centers for Disease Control and Prevention. COVID data tracker [EB/OL]. (2022-04-05) [2022-04-07]. https://covid.cdc.gov/covid-data-tracker/#variant-proportions.
    [10] Jansen L, Tegomoh B, Lange K, et al. Investigation of a SARS-CoV-2 B. 1.1.529(Omicron) variant cluster - Nebraska, November-December 2021[J]. MMWR Morb Mortal Wkly Rep, 2021, 70(5152): 1782-1784. DOI: 10.15585/mmwr.mm705152e3.
    [11] Brandal LT, Macdonald E, Veneti L, et al. Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021[J]. Euro Surveill, 2021, 26(50). DOI: 10.2807/1560-7917.ES.2021.26.50.2101147.
    [12] Lee JJ, Choe YJ, Jeong H, et al. Importation and transmission of SARS-CoV-2 B. 1.1.529(Omicron) variant of concern in Korea, November 2021[J]. J Korean Med Sci, 2021, 36(50): e346. DOI: 10.3346/jkms.2021.36.e346.
    [13] Kim MK, Lee B, Choi YY, et al. Clinical characteristics of 40 patients infected with the SARS-CoV-2 omicron variant in korea [J]. J Korean Med Sci, 2022, 37(3): e31. DOI: 10.3346/jkms.2022.37.e31.
    [14] Baker JM, Nakayama JY, O'hegarty M, et al. SARS-CoV-2 B. 1.1.529(Omicron) variant transmission within households - four U.S. Jurisdictions, November 2021-February 2022[J]. MMWR Morb Mortal Wkly Rep, 2022, 71(9): 341-346. DOI: 10.15585/mmwr.mm7109e1.
    [15] Backer JA, Eggink D, Andeweg SP, et al. Shorter serial intervals in SARS-CoV-2 cases with Omicron BA. 1 variant compared with Delta variant, the Netherlands, 13 to 26 December 2021[J]. Euro Surveill, 2022, 27(6): 2200042. DOI: 10.2807/1560-7917.ES.2022.27.6.2200042.
    [16] Kremer C, Braeye T, Proesmans K, et al. Observed serial intervals of SARS-CoV-2 for the Omicron and Delta variants in Belgium based on contact tracing data, 19 November to 31 December 2021[J]. medRxiv, 2022: 2022.01.28.22269756. DOI: 10.1101/2022.01.28.22269756.
    [17] Kim D, Ali S T, Kim S, et al. Estimation of serial interval and reproduction number to quantify the transmissibility of SARS-CoV-2 omicron variant in South Korea [J]. Viruses, 2022, 14(3): 533. DOI: 10.3390/v14030533.
    [18] Liu Y, Rocklöv J. The effective reproductive number for the Omicron variant of SARS-CoV-2 is several times relative to Delta [J]. J Travel Med, 2022. DOI: 10.1093/jtm/taac037.
    [19] Pulliam JRC, Van Schalkwyk C, Govender N, et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa [J]. Science, 2022. DOI: 10.1126/science.abn4947.
    [20] European Centre for Disease Prevention and Control. Country overview report: week 122022[EB/OL]. (2022-04-06) [2022-04-07]. https://www.ecdc.europa.eu/en/covid-19/country-overviews.
    [21] Houhamdi L, Gautret P, Hoang VT, et al. Characteristics of the first 1119 SARS-CoV-2 Omicron variant cases, in Marseille, France, November-December 2021[J]. J Med Virol, 2022, 94(5): 2290-2295. DOI: 10.1002/jmv.27613.
    [22] Garrett N, Tapley A, Andriesen J, et al. High Rate of Asymptomatic Carriage Associated with Variant Strain Omicron [J]. medRxiv, 2022. DOI: 10.1101/2021.12.20.21268130.
    [23] Getz C, Kantor G. An Early Assessment of the Omicron Covid-19 Variant: Case-Fatality Rates [EB/OL]. (2022-01-17) [2022-04-17]. https://www.insight.co.za/2022/01/17/an-early-assessment-of-the-omicron-covid-19-variant-case-fatality-rates/#:~:text=Omicron%20is%20associated%20with%20a%20case-fatality%20rate%20of,and%2091.9%25%20lower%20than%20during%20the%20Delta%20period.
    [24] Advisory Board. Covid-19 roundup: Omicron is at least 40% deadlier than the flu [EB/OL]. (2022-03-11) [2022-04-07]. https://www.advisory.com/daily-briefing/2022/03/11/covid-19-roundup.
    [25] 梁万年, 刘民, 刘珏, 等. 我国新型冠状病毒肺炎疫情防控的"动态清零"策略[J]. 中华医学杂志, 2022, 102(4): 239-242. DOI: 10.3760/cma.j.cn112137-20211205-02710.

    Liang WN, Liu M, Liu J, et al. The dynamic COVID-zero strategy on prevention and control of COVID-19 in China [J]. Natl Med J Chin, 2022, 102(4): 239-242. DOI: 10.3760/cma.j.cn112137-20211205-02710.
    [26] Zhu J, Yan W, Zhu L, et al. COVID-19 pandemic in BRICS countries and its association with socio-economic and demographic characteristics, health vulnerability, resources, and policy response [J]. Infect Dis Poverty. 2021, 10(1): 97. DOI: 10.1186/s40249-021-00881-w.
    [27] 燕新华, 周明. 重大疫情下境外人员入境管控措施研究——基于新冠肺炎疫情的思考[J]. 武警学院学报, 2021, 37(3): 40-45. https://www.cnki.com.cn/Article/CJFDTOTAL-WUJI202103007.htm
    [28] Cao Y, Wang J, Jian F, et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies [J]. Nature, 2022, 602(7898): 657-663. DOI: 10.1038/s41586-021-04385-3.
    [29] Burki TK. Omicron variant and booster COVID-19 vaccines [J]. Lancet Respir Med, 2022, 10(2): e17. DOI: 10.1016/S2213-2600(21)00559-2.
    [30] Moreira ED Jr, Kitchin N, Xu X, et al. Safety and efficacy of a third dose of BNT162b2 Covid-19 vaccine [J]. N Engl J Med, 2022. DOI: 10.1056/NEJMoa220067.
    [31] Nemet I, Kliker L, Lustig Y, et al. Third BNT162b2 vaccination neutralization of SARS-CoV-2 omicron infection [J]. N Engl J Med, 2022, 386(5): 492-494. DOI: 10.1056/NEJMc2119358.
  • 加载中
计量
  • 文章访问数:  1701
  • HTML全文浏览量:  503
  • PDF下载量:  881
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-04-01
  • 修回日期:  2022-04-14
  • 网络出版日期:  2022-05-11
  • 刊出日期:  2022-05-10

目录

    /

    返回文章
    返回